The bru­tal truth is 80% of clin­i­cal tri­als face en­roll­ment de­lays. Near­ly 90% miss re­cruit­ment tar­gets. In on­col­o­gy, CNS and rare dis­ease tri­als, where pro­to­cols are com­plex and el­i­gi­ble pa­tients nar­row­ly de­fined, those de­lays are am­pli­fied by in­tense com­pe­ti­tion with de­lays cost­ing up­ward of $50,000 per day.

And yet most spon­sors still treat re­cruit­ment as an af­ter­thought—a “cam­paign” to launch af­ter sites are ac­ti­vat­ed, when the clock is al­ready tick­ing.

The biotechs win­ning in 2026 are build­ing AI-first re­cruit­ment en­gines in­to their de­vel­op­ment pro­grams from day ze­ro. Not as a nice-to-have. But as in­fra­struc­ture.

The old play­book: Ac­ti­vate sites. Wait. Hope pa­tients show up. Pan­ic when they don’t. Scram­ble for res­cue so­lu­tions 8–12 weeks lat­er.

The new stan­dard: AI-dri­ven, al­ways-on en­roll­ment en­gines that con­tin­u­ous­ly find, match, and pre-screen pa­tients—start­ing in un­der 24 hours.

Tufts CS­DD da­ta is un­for­giv­ing:

• 37% of sites un­der-en­roll
• 11% en­roll ze­ro pa­tients
• On­ly 47% of stud­ies com­plete en­roll­ment on time
• One in six stud­ies takes 2x longer than planned

In on­col­o­gy and CNS es­pe­cial­ly, com­pe­ti­tion for pa­tients is fierce, those de­lays are com­pound­ed by bio­mark­er re­quire­ments, pri­or ther­a­py lines, co­mor­bidi­ties, and dis­ease stag­ing.

Biotechs can’t af­ford to wait 8 weeks to re­al­ize a site isn’t de­liv­er­ing. They need re­al-time in­tel­li­gence and guar­an­teed re­sponse speed.

At JPM this year, the mes­sage was blunt: the fu­ture is AI-first en­roll­ment, not just last-minute dig­i­tal res­cue. With Phase III tri­al de­lays cost­ing spon­sors up­ward of $50,000 per day, the stakes are clear.

In on­col­o­gy and CNS, that means dy­nam­i­cal­ly iden­ti­fy­ing high­ly spe­cif­ic sub­pop­u­la­tions — then screen­ing for bio­mark­er sta­tus, pri­or lines of ther­a­py, co­mor­bidi­ties, con­comi­tant med­ica­tions or CNS dis­ease stage — rather than re­ly­ing on­ly on pa­tients that sites al­ready know.

Tri­al­Wire was de­signed for this en­vi­ron­ment: an AI-dri­ven en­gine built for speed to sup­port com­plex, late-stage stud­ies where every month of de­lay com­pounds both cost and com­pet­i­tive risk. The plat­form, built on Sales­force Health Cloud, en­ables spon­sors to reach nar­row­ly de­fined co­horts at scale with­out over­whelm­ing site staff. With a 24-hour start­up and risk-share pay-per-en­roll­ment mod­el, the plat­form is dis­rupt­ing the re­cruit­ment space around val­ue, se­cu­ri­ty, and re­al-time tri­al trans­paren­cy.

Tri­al­Wire ac­ti­vates in un­der 24 hours and us­es ad­vanced al­go­rithms to find the right pa­tients, AI-screen­match to de­ter­mine ex­act el­i­gi­bil­i­ty, and a so­phis­ti­cat­ed da­ta and com­mu­ni­ca­tions por­tal of­fer­ing pa­tient con­tact tools and man­age­ment for sites, and re­al-time trans­par­ent da­ta for Spon­sors and CROs. Each study fea­tures its own cus­tomized AI Agent screen­er, trained on el­i­gi­bil­i­ty and ex­clu­sion cri­te­ria, that con­stant­ly learns from thou­sands of pa­tient in­ter­ac­tions — in­clud­ing health da­ta, bio­mark­ers, and pri­or treat­ments — be­com­ing smarter and more pre­cise with every en­gage­ment.

AI-dri­ven au­toma­tion has de­liv­ered a 30–45% up­lift in el­i­gi­ble re­fer­rals ver­sus con­ven­tion­al out­reach, while cut­ting man­u­al pre-screen­ing time at sites by up to 70%. The plat­form’s site-to-re­fer­ral com­mu­ni­ca­tions sys­tem rou­tine­ly de­liv­ers 98% re­sponse rates with me­di­an times around 90 sec­onds.

“For spon­sors, that com­bi­na­tion trans­lates in­to faster, more pre­dictable en­roll­ment curves. For sites, it feels like an ex­ten­sion of their team rather than an­oth­er sys­tem to man­age,” said Fitz­patrick-Napi­er.

The tone on AI in clin­i­cal de­vel­op­ment has shift­ed from vi­sion to ver­i­fi­ca­tion. Ses­sions at JPM this year con­verged on a sin­gle idea: in­vestors now re­ward AI where it’s em­bed­ded in core clin­i­cal work­flows — not where it sits as a stand­alone ex­per­i­ment.

“Any­thing less shows up as ex­e­cu­tion risk, not in­no­va­tion risk,” said Fitz­patrick-Napi­er.

Across health­care in­vest­ment, the as­sump­tion is that AI in clin­i­cal de­vel­op­ment is the in­fra­struc­ture lay­er that pow­ers scal­able plat­forms, par­tic­u­lar­ly in late-stage on­col­o­gy and CNS, where the bulk of R&D spend and com­pet­i­tive risk now sits.

“Tri­al­Wire re­flects that shift. It’s built as an in­fra­struc­ture-grade plat­form on top of en­ter­prise-lev­el health cloud tech­nol­o­gy, with role-based ac­cess for sites, spon­sors and CROs, and a foot­print de­signed to be ac­cept­able to reg­u­la­tors and en­ter­prise IT teams,” said Fitz­patrick-Napi­er.

• What will AI ac­tu­al­ly change for my tri­als?

AI is mov­ing re­cruit­ment from re­ac­tive bursts to a con­tin­u­ous­ly learn­ing ca­pa­bil­i­ty that au­to­mates el­i­gi­bil­i­ty match­ing at scale. In on­col­o­gy and CNS, that means en­cod­ing dis­ease-spe­cif­ic and bio­mark­er log­ic di­rect­ly in­to match­ing al­go­rithms and us­ing re­al-world da­ta to sur­face pa­tients who would nev­er ap­pear on a tra­di­tion­al site list.

Near­ly half of in­ves­tiga­tive sites ei­ther un­der-en­roll or en­roll no pa­tients at all, and around 30% of a tri­al’s costs can be tied to en­roll­ment ac­tiv­i­ties — mak­ing any up­lift in hit rate and pre­dictabil­i­ty dis­pro­por­tion­ate­ly valu­able in high-cost, late-stage pro­grams.

• Is AI-dri­ven re­cruit­ment ac­cept­able to reg­u­la­tors, sites and pa­tients?

Reg­u­la­tors glob­al­ly are sig­nal­ing sup­port for re­spon­si­ble AI use where there’s trans­paren­cy, hu­man over­sight and strong da­ta pro­tec­tion. On­col­o­gy and neu­rol­o­gy cen­ters are re­spond­ing well to AI-dri­ven out­reach when the ex­pe­ri­ence is fric­tion­less and re­spect­ful. For sites, AI au­toma­tion that cuts pre-screen­ing work by 70% frees ca­pac­i­ty for pa­tient care and pro­to­col com­pli­ance.

• Can we trust AI on bias, da­ta qual­i­ty and ethics?

Gov­er­nance has be­come the re­al bat­tle­ground. Tri­al­Wire’s ro­bust ar­chi­tec­ture on Sales­force Health Cloud re­sponds di­rect­ly to that ex­pec­ta­tion. It sep­a­rates iden­ti­fi­able pa­tient in­for­ma­tion at the site lev­el from spon­sor- and CRO-fac­ing mon­i­tor­ing dash­boards, main­tains de­tailed logs of re­cruit­ment ac­tiv­i­ty, and is de­signed to meet strin­gent pri­va­cy and se­cu­ri­ty stan­dards.

Biotechs that em­brace AI-first en­roll­ment ar­chi­tec­ture now aren’t just op­ti­miz­ing a tac­ti­cal prob­lem — they’re build­ing a struc­tur­al ad­van­tage in a mar­ket where time­lines, costs and da­ta qual­i­ty are non-ne­go­tiable com­pet­i­tive met­rics.

For spon­sors, the cal­cu­lus is straight­for­ward: de­lay AI adop­tion in en­roll­ment, and you sig­nal ex­e­cu­tion risk. Em­bed it from day ze­ro — es­pe­cial­ly in on­col­o­gy, CNS and rare dis­eases — and you own the time­lines and pre­dictabil­i­ty that in­vestors re­ward.

Tri­al­Wire was built for spon­sors who want a new ap­proach: an AI-pow­ered re­cruit­ment en­gine that can start or re­boot a stalled tri­al in un­der 24 hours, plug in­to any CRO or de­vel­op­ment plan, of­fer a risk-share mod­el and open the doors to the pa­tients who need them most.

Will Hunt­ing­ton’s dis­ease pa­tients be will­ing to ris